Traditional vaccinations are often very costly and in short supply, according to Dr. Hefferon.
Plant-based vaccinations do not require needles, syringes, or training for their administration. Quite often, they can be stored ambiently, reducing the need for expensive cold storage systems. As such, they can assist to alleviate some of the difficulties encountered with large-scale vaccination programs in developing countries.
Hefferon discussed how plants may be used to increase the availability of inexpensive medications to even more remote locations. With only 6.7 percent of low-income individuals receiving at least their first dose of a COVID-19 vaccine (as of February 2022), a decision is critical.
The SARS-CoV-2 spike protein is the key antigen to promote robust immunity against the virus, according to Hefferon''s latest research. We have added some prolines into a furin domain, which allows the protein to be purified. We have replaced [the transmembrane domain] with a KDEL motif, which is an endoplasmic reticulum retainer.
A geminivirus is then used to infect plants and causes the transient expression of the spike protein open reading frame.
The spike protein produced by plants may be used to make a cheap vaccination for people around the world.
Two biopharma companies have entered plant-based COVID-19 vaccinations into clinical trials at the time of writing.
Click here to see the whole Teach Me in the ten video!
The majority of Ebola virus cases and infections have occurred in Africa. Inmazeb and Ebanga are two monoclonal antibodies that simultaneously link to the virus glycoprotein. A vaccination for the most deadly species of ebolavirus has been approved in the United States.
The Middle East respiratory syndrome (MERS) is caused by a coronavirus infection and was first reported in Saudi Arabia in 2012, but there have been over 27 countries outside the Peninsula, in 2015, when transmission is through close contact with an infected person. There are currently no specific therapies for MERS, and vaccinations are in clinical trials.
COVID-19 is a serious acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first cases of COVID-19 were reported in China in 2019 and the virus has since spread worldwide. Numerous vaccinations have been developed and administered, with the WHO highlighting the importance of vaccine equity.
References to the following: